IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

IN8bio (Nasdaq: INAB) announced presentations and new clinical data on its γδ T cell programs at multiple May–June 2026 conferences, and an R&D Day on May 21, 2026.

Rhea-AI Summary

IN8bio (Nasdaq: INAB) announced presentations and new clinical data on its γδ T cell programs at multiple May–June 2026 conferences, and an R&D Day on May 21, 2026. Key items include a Phase I INB-200 GBM poster at ASCO June 1, 2026, an ASGCT oral presentation, ISCT posters, and R&D Day details.

Materials will be posted on the company's investor website after each meeting.

Positive

• ASCO poster on INB-200 Phase I in GBM scheduled for June 1, 2026
• R&D Day on May 21, 2026 to showcase TCE platform and clinical pipeline
• ASGCT oral presentation (May 14, 2026) highlights scientific recognition

Negative

• INB-200 data are from a Phase I study, reflecting early-stage clinical evidence
• Press release does not disclose quantitative survival or safety metrics for GBM patients

Argus May 6 session

-2.47% close to close Open Argus

Details

News Market Reaction – INAB

On May 6, the day this news came out, INAB closed 2.47% below the previous close.

Data tracked by StockTitan Argus for the May 6 session.

Key Figures

R&D Day duration: 9:00 AM–11:30 AM EDT ISCT poster time: 18:00–19:30 GMT ISCT poster ID: Poster 1253 +5 more

R&D Day duration

9:00 AM–11:30 AM EDT

IN8bio R&D Day on May 21, 2026

ISCT poster time

18:00–19:30 GMT

ISCT 2026 GBM γδ T cell therapy poster on May 7, 2026

ISCT poster ID

Poster 1253

Unraveling Complexity γδ T cell therapy in glioblastoma

ASGCT oral slot

11:00 AM–11:15 AM EDT

ASGCT 2026 oral on γδ T cells in glioblastoma

ASCO poster time

1:30 PM–4:30 PM CT

ASCO 2026 INB-200 Phase I GBM poster on June 1, 2026

ASCO poster detail

Poster 442 (Abstract 552638)

INB-200 Phase I autologous γδ T cells in newly diagnosed GBM

Conference window

May–June 2026

Series of medical and scientific conference presentations

Pre-news price move

0.62%

INAB 24h price change prior to article publication

Previous Clinical trial Reports

5 past events · Latest: Jan 12

Same Type 5 events

1. Jan 12

   GBM survival update

   24h Move

   -7.2%

   Updated Phase 1/2 DeltEx DRI GBM data showing improved survival versus SOC.

2. Oct 29

   INB-100 site expansion

   24h Move

   -4.8%

   Added Ohio State as new INB-100 Phase 1 trial site to aid enrollment.

3. Jun 02

   INB-200 Phase 1 data

   24h Move

   -9.8%

   Positive INB-200 Phase 1 GBM results with prolonged progression-free survival.

4. May 14

   INB-619 preclinical data

   24h Move

   -8.3%

   Preclinical INB-619 TCE data showing B cell elimination in lupus samples.

5. Feb 14

   INB-100 AML data

   24h Move

   -10.0%

   Phase 1 INB-100 AML data with durable remissions and strong survival rates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gamma-delta (γδ) t cell, t cell engager (tce), glioblastoma (gbm), autologous, +4 more

8 terms

gamma-delta (γδ) t cell medical

"developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune"

A gamma-delta (γδ) T cell is a small, specialized type of white blood cell that helps detect and attack infected or abnormal cells; unlike most T cells, it recognizes threats in a more general way and can respond rapidly. Investors pay attention because these cells are targets or tools in drug and cell‑therapy development, so data about their behavior can strongly influence a therapy’s effectiveness, safety profile, trial results, regulatory outlook and commercial potential — like a security team that shapes whether a new product is trusted and adopted.

t cell engager (tce) medical

"including its novel T cell engager (TCE) and clinical γδ T cell therapy programs."

A T‑cell engager is a type of drug that acts like a molecular matchmaker, physically linking a patient’s T cells (immune fighters) to a target cell such as a cancer cell so the immune system can kill it. For investors, these therapies matter because they can offer powerful, targeted treatment with high commercial upside if safe and effective, but they also carry clinical trial, manufacturing and safety risks that can create sharp swings in a company’s value.

glioblastoma (gbm) medical

"supporting the observed survival benefits in DeltEx DRI treated glioblastoma (GBM) patients."

An aggressive primary brain tumor that grows quickly and damages surrounding brain tissue, often with poor prognosis and limited effective treatments. It matters to investors because the high unmet medical need makes successful therapies commercially valuable and regulatory outcomes or clinical trial results can sharply change a biotech or pharmaceutical company’s prospects—think of it like a fast-moving weed in a garden that’s hard to remove and creates strong demand for a reliable solution.

autologous medical

"gene-modified autologous gamma delta (γδ) T cells in newly diagnosed glioblastoma"

Autologous describes a medical product or treatment made from a patient’s own cells or tissues rather than from a donor. For investors, autologous approaches matter because they can lower the risk of immune rejection and improve effectiveness, but they often require individualized manufacturing, complex logistics, and higher per-patient costs—factors that affect scalability, pricing, and regulatory hurdles in healthcare businesses.

phase i study regulatory

"INB-200: Phase I study and characterization of gene-modified autologous gamma"

A phase I study is the first stage of testing a new drug or medical treatment in people, done with a small group to check safety, side effects and appropriate dose levels while occasionally looking for early signs it might work. For investors it’s an early risk checkpoint: positive Phase I results reduce uncertainty and can increase a company’s value, while problems can significantly delay development or end a program—like road‑testing a prototype before deciding to mass‑produce it.

poster presentation technical

"2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Chicago, IL)Poster Presentation"

A poster presentation is a visual display of information, often used to share research findings or ideas at conferences or meetings. It usually consists of a large printed poster that summarizes key points, allowing viewers to quickly understand the main message and ask questions. For investors, it highlights important developments or insights in a clear, accessible way, helping them stay informed about new opportunities or trends.

oral presentation technical

"American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting (Boston, MA)Oral Presentation"

A spoken report given to an audience that summarizes facts, results or plans—often delivered at conferences, meetings or investor events. Investors watch oral presentations because they can reveal new data, management plans or interpretations that affect a company’s prospects; like hearing a coach explain a game plan, the tone, detail and emphasis can change expectations and market reactions almost immediately.

research and development (r&d) day technical

"IN8bio will also host a Research and Development (R&D) Day on May 21, 2026"

An research and development (R&D) day is a company-hosted presentation where management and technical staff explain current projects, future plans, timelines and resources for product development or innovation. Investors use it like a product demo and roadmap meeting to judge whether the company’s research is progressing as promised and whether spending is likely to produce valuable products or savings; it can affect confidence, valuations and investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical and scientific conferences in May and June 2026, including new clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting. IN8bio will also host a Research and Development (R&D) Day on May 21, 2026, showcasing advances across its γδ T cell pipeline, including its novel T cell engager (TCE) and clinical γδ T cell therapy programs.

“We look forward to sharing progress across our γδ T cell platforms at our R&D Day and several key meetings this quarter,” said William Ho, Chief Executive Officer and Co-Founder of IN8bio. “These presentations highlight the progress we are making with our novel TCE program, complemented by translational advances in our clinical program supporting the observed survival benefits in DeltEx DRI treated glioblastoma (GBM) patients. The unique properties of γδ T cells enable them to address key challenges in TCE development and to meaningfully improve outcomes in difficult-to-treat cancers.”

Presentation details are outlined below:

IN8bio 2026 R&D Day (New York, New York)
In-person and Virtual

• Featuring presentations on our T cell engager (TCE) platform for autoimmune diseases and our clinical program in GBM, with a clinical perspective from renowned neuro-oncologist Dr. David Reardon, Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
• Date and Time: May 21, 2026, 9:00 AM to 11:30 AM EDT
• Register Online: https://investors.in8bio.com/news-events/events-presentations
  
  

International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting (Dublin, Ireland)
Poster Presentations

• Title: Unraveling Complexity: The Impact, Interactions and Outcomes of a γδ T Cell Therapy in Glioblastoma
  Poster Details: 1253
  Presenter: Mariska ter Haak
  Date/Time: May 7, 2026, 18:00 to 19:30 GMT (1:00 PM to 2:30 PM EDT)

• Title: Lean Infrastructure for CGT Early-Stage Companies: Leveraging Integrated Digital Platforms to Achieve Sustainable Operation Efficiency and Scalable Compliance
  Poster Details: 801
  Presenter: Guoling Chen
  Date/Time: May 7, 2026, 18:00 to 19:30 GMT (1:00 PM to 2:30 PM EDT)

American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting (Boston, MA)
Oral Presentation

• Title: Challenging the Glioblastoma Status Quo: Could γδ T Cells Shift the Balance?
  Abstract: 328
  Presenter: Mariska ter Haak
  Date and Time: May 14, 2026, 11:00 AM to 11:15 AM EDT

2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Chicago, IL)
Poster Presentation

• Title: INB-200: Phase I study and characterization of gene-modified autologous gamma delta (γδ) T cells in newly diagnosed glioblastoma multiforme (GBM)
  Poster Details: 442 (Abstract 552638)
  Presenter: Louis B. Nabors, MD
  Date/Time: June 1, 2026, 1:30 PM to 4:30 PM CT (2:30 PM to 5:30 PM EDT)

Following each conference, posters and presentation materials will be available in the Events and Presentations section of the Company’s investor website.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will IN8bio (INAB) present at its May 21, 2026 R&D Day?

The company will present advances across its γδ T cell pipeline, including its TCE platform and clinical GBM program. According to the company, the event runs 9:00–11:30 AM EDT and will be available in-person and virtually, with presentation materials posted afterward.

When and where will IN8bio (INAB) present INB-200 Phase I GBM data at ASCO 2026?

IN8bio will present a poster on INB-200 at ASCO on June 1, 2026, 1:30–4:30 PM CT. According to the company, the poster (Abstract 552638, Poster 442) covers Phase I study details and characterization of gene-modified autologous γδ T cells.

Does IN8bio (INAB) have oral conference visibility in May 2026?

Yes. The company has an oral presentation at ASGCT on May 14, 2026, titled on γδ T cells and glioblastoma. According to the company, the talk (Abstract 328) is scheduled for 11:00–11:15 AM EDT and will be delivered by Mariska ter Haak.

Will IN8bio (INAB) share presentation materials after the conferences?

Yes. According to the company, posters and presentation materials will be posted in the Events and Presentations section of its investor website after each conference. Investors can access slides and posters following the listed conference dates.

What stage is IN8bio's INB-200 program for glioblastoma reported at ASCO 2026?

The INB-200 program is a Phase I study in newly diagnosed glioblastoma, indicating early clinical development. According to the company, the ASCO poster presents Phase I characterization of gene-modified autologous γδ T cells.

How do IN8bio's May–June 2026 presentations affect visibility for INAB investors?

The conference schedule increases scientific and investor visibility through multiple posters and an R&D Day in May and June 2026. According to the company, this includes ASGCT oral visibility and an ASCO poster, with materials posted online after events.